Caris Target Now(TM) Targets Cancer Treatment Selection
(firmenpresse) - IRVING, TX -- (Marketwire) -- 11/29/11 -- As research into cancer care advances, physicians can now take better aim in the care of their cancer patients, using evidence-based molecular profiling to help determine which cancer therapies are more likely to be effective and which therapies are likely to be ineffective.
A new evidence-based molecular profiling system -- called ™ -- is bringing about dramatic changes in the personalization of cancer care.
No two cancers are alike and cancer treatment plans shouldn't be either. Treatment that works well for one person may be ineffective for another, because each patient's cancer has different genetics. ™ makes it possible to detect those differences, match a tumor's genetics with specific drugs more likely to be effective, and flag therapies with less chance of working.
Personalized cancer treatment like this can increase quality of life, uncover treatments previously not considered, and cut healthcare costs.
One multicenter study conducted by , and , showed that ™ molecular profiling increased progression free survival from various cancers, including late-stage cancer, in 27 percent of 86 patients studied who had their therapy selected this way, versus the previous therapy on which they had progressed.
Sandeep K. Reddy, MD, oncology expert and clinical associate professor of medicine, Geffen/UCLA School of Medicine, discusses ™, and Sandra Fehrman, a cancer patient, explains how this technology helped to extend and enhance her life, in this .
For more information about the role of molecular profiling in cancer therapy selection, patients can visit and healthcare professionals may be interested in .
Image Available:
Embedded Video Available:
Lisa Fullam
480.585.6950
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.11.2011 - 20:34 Uhr
Sprache: Deutsch
News-ID 92207
Anzahl Zeichen: 0
contact information:
Town:
IRVING, TX
Kategorie:
Family
Diese Pressemitteilung wurde bisher 224 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Caris Target Now(TM) Targets Cancer Treatment Selection"
steht unter der journalistisch-redaktionellen Verantwortung von
Caris Life Sciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
